Table 2.
Univariable analysis of the discovery cohort with cervical cancer
| OR (95% CI) | p-Value | |
|---|---|---|
| Preoperative clinical size | ||
| <2 cm | 1 (Reference) | 0.561 |
| >2 cm | 1.083 (0.828–1.417) | |
| Preoperative image size | ||
| <2 cm | 1 (Reference) | 0.002 |
| >2 cm | 2.151 (1.332–3.474) | |
| Cone biopsy before surgery | ||
| No | 1 (Reference) | <0.001 |
| Yes | 0.307 (0.166–0.596) | |
| Surgical approach | ||
| Open | 1 (Reference) | 0.049 |
| MIS | 1.605 (1.001–2.573) | |
| First surgeon | ||
| Fellow and junior surgeon | 1 (Reference) | 0.818 |
| Senior surgeon | 0.938 (0.546–1.612) | |
| Largest tumor diameter | ||
| <2 cm | 1 (Reference) | 0.005 |
| >2 cm | 1.972 (1.230–3.163) | |
| Final histological grade | ||
| 1 | 1 (Reference) | 0.096 |
| 2–3 | 1.993 (0.884–4.493) | |
| LVSI | ||
| No LVSI | 1 (Reference) | 0.470 |
| Presence of LVSI | 1.393 (0.567–3.419) | |
| Depth of invasion | ||
| Superficial <1/3 | 1 (Reference) | 0.020 |
| Intermediate or deep >1/3 | 2.307 (1.138–4.674) | |
| Margins status | ||
| Negative | 1 (Reference) | 0.048 |
| Positive or close <2 mm | 2.043 (1.005–4.151) | |
| Lymph node status | ||
| Negative | 1 (Reference) | 0.469 |
| Positive | 1.289 (0.649–2.561) | |
| FIGO staging 2018 | ||
| IB1 | 1 (Reference) | 0.003 |
| IB2–II–III <4 cm | 2.141 (1.285–3.567) | |
| Adjuvant therapy | ||
| Without adjuvant therapy | 1 (Reference) | 0.984 |
| With adjuvant therapy | 1.005 (0.630–1.602) |
Based on the existing evidence, a list of variables were chosen and the OR and 95% CI were calculated for the risk of relapse using simple logistic regression models to establish clinical and pathological variables independently associated with the outcome
OR odds ratio, CI confidence interval, MIS minimally invasive surgery, LVSI lymphovascular space invasion, FIGO International Federation of Gynecology and Obstetrics